Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to JP2021023942FpriorityCriticalpatent/JP1724665S/en
Application grantedgrantedCritical
Publication of JP1724665SpublicationCriticalpatent/JP1724665S/en
本物品は、正面視において中央下部に施された挿入口に、例えば、尿、血液等の液体サンプル等を滴下させたカートリッジを挿入して分析することができるものである。This article can be analyzed by inserting, for example, a cartridge in which a liquid sample such as urine or blood has been dripped into an insertion port provided in the lower central part in a front view.
JP2021023942F2021-11-022021-11-02
Medical diagnostic or laboratory diagnostic equipment
ActiveJP1724665S
(en)
Method for analyzing a biological sample of a subject with cancer that comprises determining a level of expression of the biomarkers gli-1, otx-2, shroom2, pdlim3, and sphk1 in said sample, wherein the expression level of the biomarkers in co-operation With a control, it provides a diagnostic indicator of whether the subject has an increased probability of response to: a methyl-4'-trifluoromethoxy-biphenyl-3-carboxylic acid [6- (cis-2,6-dimethyl-morpholino-4 -yl) -pyridin-3-yl] -amide, or 2 - [(r) -4- (6-benzyl-4,5-dimethyl-pyridazin-3-yl) -2-methyl-3,4,5 , 6-tetrahydro-2h- [1,2 '] bipyrizanyl-5'-yl] -propan-2-ol; method for selecting a subject who has cancer for treatment with one of said compounds, which comprises determining the level of expression of shroom2 or sphk1, in a biological sample of the subject.